蛋白水解靶向嵌合体类药物及其潜在风险分析

doi:10.19803/j.1672-8629.20240423

摘要/Abstract

摘要： 目的介绍靶向蛋白质降解（TPD）技术中“蛋白水解靶向嵌合体（PROTACs）”技术的作用机制和设计原理,讨论现有基于PROTACs技术药物的潜在风险及解决方案,以期为新型、高效且安全性较高的PROTACs类药物研发提供参考。方法分析近年来已发表的相关文献信息,归纳PROTACs技术的作用机制、各组成部分的设计原理、已发现的潜在风险及已报道的应对策略。结果对PROTACs类药物的设计,多从靶蛋白结合分子的溶剂暴露区域选择合适的位点与连接链结合,同时该设计应基于高分辨率的晶体结构,并且应避免小分子与靶蛋白的结合亲和力发生变化;在E3连接酶及其配体选择上,多是先从使用较为广泛的CRBN和VHL连接酶配体开始进行逐步筛选;在连接链设计上,多是从柔性PEG类链开始筛选;在潜在风险上,PROTACs类药物存在如过度降解、脱靶毒性、Hook效应、代谢产物毒性、醛氧化酶参与代谢、linker断裂型产物毒性等问题。结论建议将PTOTACs化合物视为整体看待,灵活应用蛋白质组学等技术方法,预防与监测分析该类化合物的代谢产物毒性,为开发活性更好、安全性更高的PROTACs药物奠定基础。

关键词: 靶向蛋白质降解, 蛋白水解靶向嵌合体, 潜在风险, 蛋白质组学, 安全性

Abstract: Objective To introduce the mechanism and design principles of protein hydrolysis targeting chimeras (PROTACs) in Targeted Protein Degradation (TPD) technology, and to discuss the potential risks of and solutions to existing PROTACs based drugs in order to provide reference for the development of new, efficient and safe PROTAC drugs. Methods Relevant literature published in recent years was analyzed. The mechanism of PROTACs technology, design principles of each component, identified potential risks, and corresponding response strategies were summarized. Results For the design of PROTAC drugs, suitable sites and connecting chains should be selected from the solvent exposure areas of target protein binding molecules. At the same time, this design should be based on high-resolution crystal structures and avoid changes in the binding affinity between small molecules and target proteins. For the selection of E3 ligases and their ligands, screening usually starts with the widely used CRBN and VHL ligands. In the design of connecting chains, screening often starts from flexible PEG chains. In terms of potential risks, PROTAC drugs can cause such problems as excessive degradation, off target toxicity, Hook effect, metabolite toxicity, involvement of aldehyde oxidase in metabolism, and linker cleavage product toxicity. Conclusion PTOTAC compounds should be viewed as a whole, and proteomics and other technical methods should be flexibly applied to prevent, monitor and analyze the toxicity of their metabolites so as to facilitate the development of more active and safe PROTAC drugs.

Key words: targeted protein degradation, proteolysis targeting chimeras, potential risks, proteomics, security

中图分类号:

R977
R979.1

姜海伦, 周辛波, 肖典, 钟武, 李松. 蛋白水解靶向嵌合体类药物及其潜在风险分析[J]. 中国药物警戒, 2024, 21(7): 730-734.

JIANG Hailun, ZHOU Xinbo, XIAO Dian, ZHONG Wu, LI Song. Proteolysis targeting chimeric drugs and their potential risks[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 730-734.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240423

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I7/730

参考文献

[1] GOPALSAMY A.Selectivity through targeted protein degradation(TPD) miniperspective[J]. Journal of Medicinal Chemistry, 2022, 65(12): 8113-8126.
[2] LI X, PU W, ZHENG Q, et al.Proteolysis-targeting chimeras (PROTACs) in cancer therapy[J]. Molecular Cancer, 2022, 21(1): 99.
[3] WANG C, WANG H, ZHENG C, et al.Discovery of coumarin-based MEK1/2 PROTAC effective in human cancer cells[J]. ACS Medicinal Chemistry Letters, 2022, 14(1): 92-102.
[4] XIANG W, ZHAO L, HAN X, et al.Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer[J]. Journal of Medicinal Chemistry, 2021, 64(18): 13487-13509.
[5] WU Y, PU C, FU Y, et al.NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion[J]. Acta Pharmaceutica Sinica B, 2022, 12(6): 2859-2868.
[6] YANG T, HU Y, MIAO J, et al.A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization[J]. Acta Pharmaceutica Sinica B, 2022, 12(6): 2658-2671.
[7] WANG F, ZHAN Y, LI M, et al.Cell-permeable PROTAC degraders against KEAP1 efficiently suppress hepatic stellate cell activation through the antioxidant and anti-inflammatory pathway[J]. ACS Pharmacology & Translational Science, 2022, 6(1): 76-87.
[8] BASSI ZI, FILLMORE MC, MIAH AH, et al.Modulating PCAF/GCN5 immune cell function through a PROTAC approach[J]. ACS Chemical Biology, 2018, 13(10): 2862-2867.
[9] KARGBO RB.PROTAC degradation of IRAK4 for the treatment of neurodegenerative and cardiovascular diseases[J]. ACS Med Chem Letc, 2019, 10(9): 1251-1252.
[10] HE Y, KHAN S, HUO Z, et al. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies[J]. Journal of Hematology & Oncology, 2020, 13: s13045-020-00924-z.
[11] YAU R, RAPE M.The increasing complexity of the ubiquitin code[J]. Nature Cell Biology, 2016, 18(6): 579-586.
[12] KOMANDER D, RAPE M.The ubiquitin code[J]. Annual Review of Biochemistry, 2012, 81: 203-229.
[13] KAZMIERSKI WM, KENAKIN TP, GUDMUNDSSON KS.Peptide, peptidomimetic and small‐molecule drug discovery targeting HIV‐1 host‐cell attachment and entry through gp120, gp41, CCR5 and CXCR4[J]. Chemical Biology & Drug Design, 2006, 67(1): 13-26.
[14] JIANG X, YU J, ZHOU Z, et al.Molecular design opportunities presented by solvent‐exposed regions of target proteins[J]. Medicinal Research Reviews, 2019, 39(6): 2194-2238.
[15] CAO C, HE M, WANG L, et al.Chemistries of bifunctional PROTAC degraders[J]. Chemical Society Reviews, 2022, 51(16): 7066-7114.
[16] SCHAPIRA M, CALABRESE MF, BULLOCK AN, et al.Targeted protein degradation: expanding the toolbox[J]. Nature Reviews Drug Discovery, 2019, 18(12): 949-963.
[17] EMERT-SEDLAK LA, TICE CM, SHI H, et al.PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication[J]. Cell Chemical Biology, 2024, 31(4): 658-668.
[18] DE WISPELAERE M, DU G, DONOVAN KA, et al.Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations[J]. Nature Communications, 2019, 10(1): 3468.
[19] ZHAO J, WANG J, PANG X, et al.An anti-influenza a virus microbial metabolite acts by degrading viral endonuclease PA[J]. Nature Communications, 2022, 13(1): 2079.
[20] LI H, WANG S, MA W, et al.Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders[J]. Journal of Medicinal Chemistry, 2022, 65(10): 7154-7169.
[21] HAHN F, HAMILTON ST, WANGEN C, et al.Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity[J]. International Journal of Molecular Sciences, 2021, 22(23): 12858.
[22] ALUGUBELLI YR, XIAO J, KHATUA K, et al.Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease[J]. Journal of Medicinal Chemistry, 2024, 67(8): 6495-6507.
[23] CHAKRAVARTY A, YANG PL.Targeted protein degradation as an antiviral approach[J]. Antiviral Research, 2023, 210: 105480.
[24] CHOUDHURY NR, HEIKEL G, MICHLEWSKI G.TRIM25 and its emerging RNA‐binding roles in antiviral defense[J]. Wiley Interdisciplinary Reviews: RNA, 2020, 11(4): e1588.
[25] TROUP RI, FALLAN C, BAUD MG.Current strategies for the design of PROTAC linkers: a critical review[J]. Exploration of Targeted Anti-tumor Therapy, 2020, 1(5): 273-312.
[26] XIA LW, BA MY, LIU W, et al.Triazol: a privileged scaffold for proteolysis targeting chimeras[J]. Future Medicinal Chemistry, 2019, 11(22): 2919-2973.
[27] CHEN Y, TANDON I, HEELAN W, et al.Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation[J]. Chemical Society Reviews, 2022, 51(13): 5330-5350.
[28] KLEIN VG, TOWNSEND CE, TESTA A, et al.Understanding and improving the membrane permeability of VH032-based PROTACs[J]. ACS Medicinal Chemistry Letters, 2020, 11(9): 1732-1738.
[29] POONGAVANAM V, ATILAW Y, SIEGEL S, et al.Linker-dependent folding rationalizes PROTAC cell permeability[J]. Journal of Medicinal Chemistry, 2022, 65(19): 13029-13040.
[30] HEMKENS M, STAMP K, LOBERG LI, et al.Industry perspective on the nonclinical safety assessment of heterobifunctional degraders[J]. Drug Discovery Today, 2023, 28(8): 103643.
[31] NGUYEN TM, SREEKANTH V, DEB A, et al.Proteolysis-targeting chimeras with reduced off-targets[J]. Nature Chemistry, 2024, 16(2): 218-228.
[32] GORACCI L, DESANTIS J, VALERI A, et al.Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications[J]. Journal of Medicinal Chemistry, 2020, 63(20): 11615-11638.
[33] DALVIE D, XIANG C, KANG P, et al.Interspecies variation in the metabolism of zoniporide by aldehyde oxidase[J]. Xenobiotica, 2013, 43(5): 399-408.
[34] PIKE A, WILLIAMSON B, HARLFINGER S, et al.Optimizing proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective[J]. Drug Discovery Today, 2020, 25(10): 1793-1800.
[35] JONES LH, MITCHELL CA, LOBERG L, et al.Targeted protein degraders: a call for collective action to advance safety assessment[J]. Nature Reviews Drug Discovery, 2022, 21(6): 401-402.